Purchase Order 75N93021P00868

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $17,112.96 on April 22, 2021, for GMP FLT-3L, GMP SCF, and GMP TPO reagents (50 micrograms each). Performance is scheduled in Germany with an ultimate completion date of April 30, 2021. The order is firm fixed price with no set-aside designation.</p>

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $103,103.00 firm fixed-price purchase order contract to Cellgenix USA, a division of Cellgenix GMBH, a for-profit manufacturer of goods. The contract, which had no set-aside designation, is for the provision of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, interleukin-4, and other cell therapy reagents to support federal cell and gene therapy research...

This is a federal contract award to Amgen USA Inc., a division of the biotechnology company Amgen, by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. The contract, valued at $37,675,456.54, is for the acquisition of a colony stimulating factor, either G-CSF or GM-CSF, to mitigate neutropenia arising from exposure to ionizing radiation. This is a delivery order contract under the HHS Colony Stimulating Factor 2013-2018 IDIQ contract, a...

This federal contract award, valued at $98,077.50, was issued by the National Cancer Institute (NCI), an agency within the U.S. Department of Health and Human Services, to Sartorius Stedim North America Inc. The contract is for the purchase of CellGenix GMP rh IL-4 50ug vials to support cancer vaccine research and clinical trials conducted by the NCI's Center for Cancer Research, Vaccine Branch. This is a firm fixed-price purchase order contract with a completion date of September 30, 2022....

The Food and Drug Administration (FDA) awarded a purchase order to Genscript USA Inc. on July 12, 2019, for the development of a stable cell line expressing target antibody 41, with a ceiling value of $20,285.30. This firm fixed-price contract, which concluded on December 31, 2019, represents a focused procurement for specialized biotechnology services to support the FDA's research and development initiatives. The work was performed at Genscript's facility in Piscataway, New Jersey, where the...

The Department of Health and Human Services National Institutes of Health Clinical Center awarded Miltenyi Biotec, Inc. a $365,751 firm fixed price contract for the provision of a CliniMACS Prodigy Instrument with installation and training services. The solicitation sought the CliniMACS system, which is a closed loop, fully automated cell isolation system with pre-programmed selection and depletion protocols, to be used in the new Center for Cellular Engineering cGMP Facility located in...

This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Peprotech Inc., a biotechnology company that develops and manufactures cytokine products. The $3,560.00 Firm Fixed Price Purchase Order is for the delivery of recombinant human M-CSF 250 ug, a biological reagent material used in research. Peprotech Inc. has received several prior awards from the Department of Health and Human Services (HHS), National Institutes of Health (NIH), and other...

The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $9,210.00 to Fisher Scientific Company L.L.C. on December 11, 2025, for GIBCO Human GM-CSF Recombinant Protein, with an ultimate completion date of December 29, 2025. The contract utilizes a fixed-price pricing structure with economic price adjustment provisions and carries no set-aside designation, indicating open competition. Performance will take place in Pittsburgh, Pennsylvania, where Fisher Scientific...

Genentech USA, Inc. was awarded a $6,521.52 delivery order against the Defense Logistics Agency Troop Support Medical indefinite-delivery/indefinite-quantity contract to provide 4556727078 units of ActiVase 50 mg vials with diluent for injection. The place of performance will be Genentech's facility located in South San Francisco, California. The period of performance for this firm-fixed-price order is March 29, 2022 through April 1, 2022. No subcontractors or set-aside designations were...

The Department of Veterans Affairs (VA) Veterans Health Administration Veterans Integrated Service Network 8 awarded a firm fixed price delivery order contract to CSL Behring L.L.C., a global biotherapeutics company, to provide the pharmaceutical product PRIVIGEN in 5 GM, 10 GM, and 20 M doses. The $136,441.88 contract was awarded on March 4, 2020 with a performance period ending March 31, 2020. This order was placed against CSL Behring's Pharmaceuticals and Drugs Federal Supply Schedule...